News
PHIO
1.050
+0.96%
0.010
Weekly Report: what happened at PHIO last week (0720-0724)?
Weekly Report · 17h ago
Phio Pharma corrects date for Renmark virtual non-deal roadshow presentation
PUBT · 5d ago
Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Newsfile · 5d ago
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Newsfile · 5d ago
Phio Pharmaceuticals adds dermatology expert to board
TipRanks · 6d ago
Phio Pharmaceuticals names dermatologist R. Todd Plott to board
PUBT · 6d ago
Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors
Newsfile · 6d ago
Weekly Report: what happened at PHIO last week (0713-0717)?
Weekly Report · 07/20 09:52
Phio Secures Additional Patent Protection In US, Canada, Japan For INTASYL Compounds
NASDAQ · 07/17 15:17
Phio Pharmaceuticals Announces Multiple Favorable Patent Actions Encompassing Three Notices Of Allowance And One Grant Decision
Benzinga · 07/15 11:06
Phio Pharma wins US, Canada patent allowances for INTASYL siRNA compounds
PUBT · 07/15 11:04
Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision
Newsfile · 07/15 11:00
Weekly Report: what happened at PHIO last week (0706-0710)?
Weekly Report · 07/13 09:53
Weekly Report: what happened at PHIO last week (0629-0703)?
Weekly Report · 07/06 09:56
Weekly Report: what happened at PHIO last week (0622-0626)?
Weekly Report · 06/29 09:53
Phio Pharmaceuticals to present at Renmark virtual non-deal roadshow
PUBT · 06/26 11:01
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Newsfile · 06/26 11:00
Phio Pharma To Discuss siRNA Oncology At Force Family Office Fireside Chat; INTASYL Program Positioned As Differentiated Immuno‑Oncology Strategy
Benzinga · 06/25 11:19
Phio Pharma CEO Bitterman joins Force Family Office fireside chat on siRNA cancer therapy
PUBT · 06/25 11:02
Phio Pharmaceuticals Commences Manufacturing The First Commercial-scale Batch Of PH-762 Drug Substance At Nitto Denko Avecia
Benzinga · 06/24 11:05
More
Webull provides a variety of real-time PHIO stock news. You can receive the latest news about Phio Pharmaceuticals Corp through multiple platforms. This information may help you make smarter investment decisions.
About PHIO
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.